The impact of EU pharmaceutical reform
Pf Media
by Emma Morriss
4d ago
Uniphar was delighted to welcome European industry leaders to Zurich to debate the proposed EU pharmaceutical legislation reform, and incoming HTA reform. The conversation was held against the backdrop of the EU elections, and discussions focused on the impact of both on the pharma industry globally. With consideration to the proposed changes to pharmaceutical legislation, the attendees of this invite-only event discussed whether the EU would become a less attractive market to launch and commercialise brands. Or whether considered in the balance of reform in the US and growth in China, by comp ..read more
Visit website
Significant advancement in drug discovery
Pf Media
by Joanna Harvey
4d ago
A potentially significant advancement in drug discovery has been achieved, after the combined computing power of Amazon Web Services (AWS) and Intel. This project was supported by an Intel RISE Technology Initiative contribution. Generating this information computationally is intensive, considering multiple possible models. Overcoming the computational challenge was possible for the Cambridge Crystallographic Data Centre (CCDC) through the combined power of Intel and AWS. The CCDC generated a comprehensive snapshot of protein cavities in the Protein Data Bank (PDB), identifying potential bindi ..read more
Visit website
Positive news for patients with mantle cell lymphoma
Pf Media
by Joanna Harvey
4d ago
AstraZeneca’s results from the ECHO Phase III trial have shown that acalabrutinib in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with Mantle Cell Lymphoma. The results also showed a favourable trend in overall survival (OS) compared to standard-of-care chemoimmunotherapy in elderly patients (>65 years old) with previously untreated mantle cell lymphoma (MCL).1 MCL is a rare and typically aggressive form of non-Hodgkin lymphoma (NHL), often diagnosed as a late-stage d ..read more
Visit website
Positive data for patients with relapsed or refractory multiple myeloma
Pf Media
by Joanna Harvey
4d ago
Long-term data from a Phase 1/2 study has shown that with 20 to 30 months of median follow-up, triple class exposed patients with relapsed or refractory multiple myeloma (RRMM), treated with TALVEY®▼ (talquetamab), maintained high overall response rates (ORR) and durable responses. This was irrespective of whether they had received prior T-cell redirection therapy.1 The data, featured in a poster presentation at the 2024 European Hematology Association (EHA) Congress demonstrated the efficacy and durability of talquetamab when used before or after chimeric antigen receptor T-cell (CAR-T) thera ..read more
Visit website
Blood cancer medicine gets SMC approval
Pf Media
by Joanna Harvey
1w ago
The Scottish Medicines Consortium (SMC) has approved the use of Columvi®▼ (glofitamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), a type of blood cancer, after two or more lines of systemic therapy.* The SMC’s decision, along with previous Medicines and Healthcare products Regulatory Agency (MHRA) approval and The National Institute for Health and Care Excellence (NICE) recommendation, are based on safety and efficacy data from a Phase I/II clinical study. Glofitamab is a first in class bispecific antibody in DL ..read more
Visit website
Anaemia drug accepted for use within NHS Scotland
Pf Media
by Joanna Harvey
1w ago
GSK’s Omjjara▼ (momelotinib) has been accepted for use within NHS Scotland, in line with its licence, for eligible adult myelofibrosis patients with moderate to severe anaemia. This decision makes momelotinib the first JAK inhibitor treatment to be made available on the NHS in Scotland for both newly diagnosed and previously ruxolitinib-treated adult myelofibrosis patients with moderate to severe anaemia.1, 2 Myelofibrosis is a rare type of blood marrow cancer that disrupts the body’s normal production of blood cells. It is estimated that there are approximately 175 people living with myelofib ..read more
Visit website
Prescription costs for England published by the NHS
Pf Media
by Joanna Harvey
1w ago
The annual Prescription Cost Analysis (PCA) has been provided by the NHS, providing details of the costs and volumes of all prescriptions dispensed in the community in England. Data relating to medicines supplied as the Pharmacy First Clinical Pathways advanced service have been included. The NHS Business Services Authority (NHSBSA) has published the official 2023/24 statistics. The key findings include: the cost of prescription items dispensed in the community was £10.9 billion, a 5% increase from £10.4 billion in 2022/23. the number of prescription items dispensed in the community was 1.21 ..read more
Visit website
New partnership to improve access to antibiotics
Pf Media Magazine
by Joanna Harvey
2w ago
The Global Antibiotic Research & Development Partnership (GARDP) and the Stop TB Partnership’s Global Drug Facility (GDF), hosted by the United Nations Office for Project Services (UNOPS), have a new partnership agreement to improve global access to antibiotics. GDF will incorporate GARDP’s portfolio of antibiotics to improve appropriate and affordable antibiotic access for the benefit of patients and health systems, particularly in low and middle-income countries. Access to newer antibiotics tends to be limited to a small number of high-income countries. A 2018 study found that only 12 of ..read more
Visit website
Approval sought for non-small cell lung cancer treatment
Pf Media Magazine
by Joanna Harvey
2w ago
An application for the extension of RYBREVANT®▼ (amivantamab) marketing authorisation (line extension) has been submitted to the European Medicines Agency (EMA), to seek approval for the use of a subcutaneous (SC) formulation of amivantamab, in combination with lazertinib, for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC). The application to the EMA is supported by positive data from the Phase 3 PALOMA-3 study, which demonstrated non-inferior pharmacokinetics and efficacy for SC amivantamab combined with lazertinib compared to intravenous (IV) admi ..read more
Visit website
NHS trials personalised cancer vaccines
Pf Media Magazine
by Joanna Harvey
2w ago
Thousands of cancer patients in England are set to gain fast-tracked access to trials of personalised cancer vaccines, following the launch of a world-leading NHS ‘matchmaking’ service to help find new life-saving treatments. The NHS has already treated its first patient, Elliot Phebve, in England, with a personalised vaccine against his bowel cancer, as part of NHS England’s new Cancer Vaccine Launch Pad. Elliot received the developmental vaccine at University Hospitals Birmingham NHS Foundation Trust, one of several sites taking part in the colorectal cancer vaccine trial sponsored by BioNTe ..read more
Visit website

Follow Pf Media on FeedSpot

Continue with Google
Continue with Apple
OR